Treatment of chronic nephropathies using soluble complement receptor type I (sCR1)
US9649357B2 · kind B2 · utility
1Cited by
9References
8Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Mar 16, 2016 |
| Grant date | May 16, 2017 |
| Priority date | — |
| Expiry date | Mar 16, 2036 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method is disclosed for treating nephropathies involving undesired alternative pathway complement activation by administration of a complement inhibitory protein such as soluble complement receptor type I (sCR1).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.